Method for diagnosing, monitoring the progression of or supervising the treatment of inflammatory bowel disease, which comprises determining the levels of CD14 + HLA-DRhi monocytes in a sample obtained from a subject, where: (i) increased levels of CD14 + monocytes HLA-DRhi compared to: (a) a control sample obtained from a healthy subject； or (b) a control sample obtained from a sick subject； or (c) a predetermined threshold value calculated by statistical analysis of levels of CD14 + HLADRhi monocytes obtained from sick patients and compared to levels of CD14 + HLA-DRhi monocytes obtained from healthy subjects； indicate the existence of inflammatory bowel disease； (ii) increased levels of CD14 + HLA-DRhi monocytes compared to: (a) a sample obtained from the subject at a previous time point； or (b) a control sample obtained from a healthy subject； or (c) a control sample obtained from a sick subject； or (d) a predetermined threshold value calculated by statistical analysis of levels of CD14 + HLADRhi monocytes obtained from sick patients and compared to levels of CD14 + HLA-DRhi monocytes obtained from healthy subjects； indicate the progression of inflammatory bowel disease； or (iii) decreased levels of CD14 + HLA-DRhi monocytes correlate with successful treatment.Método para diagnosticar, supervisar la progresión de o supervisar el tratamiento de enfermedad inflamatoria del intestino, que comprende determinar los niveles de monocitos CD14+HLA-DRhi en una muestra obtenida de un sujeto, en donde: (i) niveles aumentados de monocitos CD14+HLA-DRhi en comparación con: (a) una muestra de control obtenida de un sujeto sano； o (b) una muestra de control obtenida de un sujeto enfermo； o (c) un valor umbral predeterminado calculado por análisis estadístico de niveles de monocitos CD14+HLADRhi obtenidos de pacientes enfermos y en comparación con niveles de monocitos CD14+HLA-DRhi obtenidos de sujetos sanos； indican la existencia de enfermedad inflamatoria del intestino； (ii)
